초록 ▼

The present invention is concerned with a pharmaceutical delivery device comprising a biologically acceptable silicone polymer matrix having microsealed compartments of 10-200 microns throughout, wherein the microsealed compartments contain a pharmaceutical in a hydrophilic solvent system. The biolo

The present invention is concerned with a pharmaceutical delivery device comprising a biologically acceptable silicone polymer matrix having microsealed compartments of 10-200 microns throughout, wherein the microsealed compartments contain a pharmaceutical in a hydrophilic solvent system. The biologically acceptable silicone polymer matrix is formed by in situ cross linking of a liquid, biologically acceptable silicone polymer in an emulsion of pharmaceutical in the hydrophilic solvent system and liquid biologically acceptable silicone polymer. The biologically acceptable silicone polymer matrix is placed in a sealed or unsealed biologically acceptable polymer container. The rate of release of pharmaceutical is controlled by altering the solubility characteristics of the hydrophilic solvent system and/or the biologically acceptable polymer matrix, the rate of release being independent of the time when the ratio of the partition coefficient of the pharmaceutical between the hydrophilic solvent system and biologically acceptable silicone polymer matrix to the solubility of the pharmaceutical in the hydrophilic solvent system is between 1 and 10-4 ml/mcg.

대표청구항 ▼

A microsealed pharmaceutical delivery device comprising a sectioned length of flexible medical grade silicone polymer hollow tubing as a biologically acceptable polymer container with as many perforations in the wall of the tubing when unsealed at each end as to expose up to 40% of an inner biologic

A microsealed pharmaceutical delivery device comprising a sectioned length of flexible medical grade silicone polymer hollow tubing as a biologically acceptable polymer container with as many perforations in the wall of the tubing when unsealed at each end as to expose up to 40% of an inner biologically acceptable silicone polymer matrix contained with the biologically acceptable polymer container, said biologically acceptable silicone polymer matrix having the formula [Figure] wherein R is alkoxy having 1-7 carbon atoms, alkyl having 1-10 carbon atoms, phenyl, vinyl, or allyl, wherein n is about 100-5000 and having 10-200 micron microsealed compartments throughout, said microsealed compartments containing pharmaceutical saturated 20-70 w/v% polyethylene glycol molecular weight 450-6000, 20-70 v/v% propylene glycol, or 20-70% 1-3-butanediol in water as hydrophilic solvent system.